Hansoh Pharmaceutical (03692) Announces NMPA Approval of Hengmeida® (Ibrexafungerp Citrate Tablets) for Treatment of Vulvovaginal Candidiasis

Hansoh Pharma (03692) announced that Hengmeida® (Ibrexafungerp Citrate Tablets) has been issued a drug registration certificate by the National Medical Products Administration (NMPA) for the treatment of vulvovaginal candidiasis (VVC) in adult and post-menarchal adolescent females.